New drug trial aims to tame rare blood cancer
NCT ID NCT03722407
Summary
This study is testing whether the drug ruxolitinib can help control Chronic Myelomonocytic Leukemia (CMML), a rare blood cancer. Researchers are enrolling 29 adults with CMML who have significant symptoms or an enlarged spleen. The main goal is to see if the treatment reduces symptoms, shrinks the spleen, and delays the cancer from transforming into a more aggressive form.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
Weill Medical College of Cornell University
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.